In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
- Autores
- Aparicio, Evangelina; Luthy, Isabel Alicia
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.
Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Buenos Aires Breast Cancer Symposium
Buenos Aires
Argentina
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Consejo Nacional de Investigaciones Científicas y Técnicas
Instituto de Biología y Medicina Experimental
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Investigaciones en Medicina Traslacional
Instituto de Nanosistemas
Universidad Austral
Universidad de Buenos Aires
Universidad Nacional de San Martín - Materia
-
MICRORNA
ADRENERGIC RECEPTORS
BREAST CANCER
BIOINFORMATICS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/152262
Ver los metadatos del registro completo
id |
CONICETDig_323fbb36730e3fb8ec0050d997b52ad5 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/152262 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypesAparicio, EvangelinaLuthy, Isabel AliciaMICRORNAADRENERGIC RECEPTORSBREAST CANCERBIOINFORMATICShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBuenos Aires Breast Cancer SymposiumBuenos AiresArgentinaCentro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”Consejo Nacional de Investigaciones Científicas y TécnicasInstituto de Biología y Medicina ExperimentalInstituto de Fisiología, Biología Molecular y NeurocienciasInstituto de Investigaciones en Medicina TraslacionalInstituto de NanosistemasUniversidad AustralUniversidad de Buenos AiresUniversidad Nacional de San MartínFundación Revista MedicinaKordon, Edith ClaudiaLanari, Claudia Lee MalvinaSimian, Marina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectSimposioJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/152262In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-280025-76801669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.cominfo:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:44:57Zoai:ri.conicet.gov.ar:11336/152262instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:44:57.872CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
title |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
spellingShingle |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes Aparicio, Evangelina MICRORNA ADRENERGIC RECEPTORS BREAST CANCER BIOINFORMATICS |
title_short |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
title_full |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
title_fullStr |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
title_full_unstemmed |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
title_sort |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes |
dc.creator.none.fl_str_mv |
Aparicio, Evangelina Luthy, Isabel Alicia |
author |
Aparicio, Evangelina |
author_facet |
Aparicio, Evangelina Luthy, Isabel Alicia |
author_role |
author |
author2 |
Luthy, Isabel Alicia |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Kordon, Edith Claudia Lanari, Claudia Lee Malvina Simian, Marina |
dc.subject.none.fl_str_mv |
MICRORNA ADRENERGIC RECEPTORS BREAST CANCER BIOINFORMATICS |
topic |
MICRORNA ADRENERGIC RECEPTORS BREAST CANCER BIOINFORMATICS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes. Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Buenos Aires Breast Cancer Symposium Buenos Aires Argentina Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Biología y Medicina Experimental Instituto de Fisiología, Biología Molecular y Neurociencias Instituto de Investigaciones en Medicina Traslacional Instituto de Nanosistemas Universidad Austral Universidad de Buenos Aires Universidad Nacional de San Martín |
description |
Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Simposio Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/152262 In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-28 0025-7680 1669-9106 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/152262 |
identifier_str_mv |
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-28 0025-7680 1669-9106 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com info:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.coverage.none.fl_str_mv |
Internacional |
dc.publisher.none.fl_str_mv |
Fundación Revista Medicina |
publisher.none.fl_str_mv |
Fundación Revista Medicina |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613414275514368 |
score |
13.070432 |